Company intelligence / Profile preview

Peregrine Ophthalmic

Singapore, -, Singaporeperegrineophthalmic.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Peregrine Ophthalmic has developed Lipolat, a sustained-release liposomal latanoprost product. Clinical trials have shown that a single dose can maintain significant intraocular pressure reduction over several months in glaucoma patients. The company is also conducting clinical trials to evaluate Lipolat as a non-surgical treatment for eyebags, with ongoing studies assessing safety and efficacy in reducing lower eyelid steatoblepharon volume compared to placebo.

Therapeutic areas: Ophthalmology
Modalities: Nanomedicine (liposomal drug delivery)Small molecules (latanoprost)
Industry: Biotech

Drug pipeline

1 asset

liposomal latanoprost

Partnerships

Singapore Eye Research Institute (technology licensor)Nanyang Technological University (technology licensor)

Beyond the preview

Go deeper on Peregrine Ophthalmic.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Peregrine Ophthalmic.

Explore the full profile